Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#251 of 589

Marc Goodman

Leerink Partners · Equity Research Analyst
ProvisionalRating since 2021No new ratings since Oct 2025

Analyst rating accuracy & track record

Marc Goodman is an equity research analyst at Leerink Partners. Quantellect has scored 32 of their stock calls across 19 companies. Their picks beat their sector 46% of the time over the next 12 months, and their price targets were reached 49% of the time within a year.

Win % vs sector
46%
PT Hit % (12mo)
49%
Avg sector-excess
−3.2%
Scored calls
32
Tickers
19
Tier
Provisional

Track record

Quantellect has scored 32 of Marc Goodman's stock calls across 19 companies, dating back to 2021. Their rated stocks beat their own sector 46% of the time over the next 12 months. On a typical call, a Goodman pick returned −3.2% more than its sector over the following year.

Of the scored calls, 32 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
BLTEBelite Bio Inc ADR
Buy$85.00Oct 2025+45.8%Hit
OCSOculis Holding AG Ordinary shares
Buy$50.00Oct 2025−81.7%Miss
AMLXAmylyx Pharmaceuticals Inc
Buy$20.00Oct 2025+85.7%Hit
EOLSEvolus Inc
Buy—Oct 2025+6.8%—
AXSMAxsome Therapeutics Inc
Buy—Oct 2025+27.9%—
STOKStoke Therapeutics Inc
Buy$30.00Oct 2025−38.2%Hit
JAZZJazz Pharmaceuticals PLC
Buy$215.00Oct 2025+50.0%Hit
XENEXenon Pharmaceuticals Inc
Buy—Oct 2025−25.0%—
AMLXAmylyx Pharmaceuticals Inc
Buy$20.00Oct 2025+85.7%Hit
AXSMAxsome Therapeutics Inc
Buy—Oct 2025+27.9%—
EOLSEvolus Inc
Buy—Oct 2025+6.8%—
ACADACADIA Pharmaceuticals Inc
Buy$30.00Oct 2025−25.6%Hit
BIIBBiogen Inc
Buy—Oct 2025+29.4%—
LBRXLB Pharmaceuticals Inc Common Stock
Buy$34.00Oct 2025+97.2%Hit
LBRXLB Pharmaceuticals Inc Common Stock
Buy$34.00Oct 2025+97.2%Hit
NBIXNeurocrine Biosciences Inc
Buy—Sep 2025−29.7%—
NBIXNeurocrine Biosciences Inc
Buy—Sep 2025−29.7%—
KLRSKalaris Therapeutics, Inc.
Buy$20.00Sep 2025−51.8%Miss
DNLIDenali Therapeutics Inc
Buy$40.00Aug 2025+44.3%Miss
DNLIDenali Therapeutics Inc
Buy$40.00Aug 2025+44.3%Miss
ALDXAldeyra The
Buy$10.00Aug 2025−99.7%Miss
BHVNBiohaven Ltd.
Buy$50.00Aug 2025−28.0%Miss
LENZLENZ Therapeutics Inc
Buy$36.00Aug 2025−106.5%Hit
LENZLENZ Therapeutics Inc
Buy$36.00Aug 2025−106.5%Hit
AMLXAmylyx Pharmaceuticals Inc
Buy$10.00May 2025+222.1%Hit
Prev1
Go to

Marc Goodman: analyst track record FAQ

Is Marc Goodman a good stock analyst?

Yes, by track record. Marc Goodman ranks number 251 of 589 of the analysts Quantellect scores, with an Analyst Score of 40 out of 100. Past results do not guarantee future ones.

What is Marc Goodman's win rate?

Marc Goodman's win rate is 46%. Across 32 scored calls, their rated stocks beat their sector 46% of the time over the next 12 months. On a typical call they returned −3.2% more than the sector.

What stocks and sectors does Marc Goodman cover?

Marc Goodman covers 19 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Marc Goodman's price targets accurate?

Marc Goodman's price targets are reached within 12 months 49% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Marc Goodman's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Marc Goodman rank among Wall Street analysts?

Marc Goodman ranks number 251 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.